Novavax’s, Inc. (NASDAQ:NVAX) data from phase II trials of RSV F Vaccines that will be used in women within the age of child bearing have been published in the Vaccine Journal. The company is developing the vaccine with the aim of protecting newborns from RSV conditions.

The first results from the trial were reported in April 2014. The study, mainly evaluate the immunogenicity and protection of various constructions of Novavax’ RSV-F protein nanoparticle vaccine and how they adjuvant with the aluminum phosphate elements. The prime end result from the study was the safety and immune response.

The study used a sample of 720 women good and healthy conditions between the ages of 18 – 35 years old (the age bracket for child bearing). Each woman from the sample frame got one or two intramuscular injections that contain two doses of the vaccine antigen with a trace of aluminum phosphate adjuvant content.

The data was collected in relation to the immunogenicity and general safety of the vaccine for more than 91 days after the first immunization. The data manuscripts are used to collect the essential antibody response brought out by the RSV F Vaccine in women receive the vaccine.

Most of the antibodies peaked after 14 days of the immunization and continued at higher levels for a period of three months when the immunogenicity was assessed. The findings from the baseline study showed some serologic evidence unveiling the presence of a new infection caused by RSV.

The overall findings from Phase II trial demonstrates a decrease in RSV infections of up to 52% in the vaccination relative to what the firm had reported earlier in September 2015. The combined data from all the studies imply that RSV F Vaccine provided safety and well-being against the RSV infections in the sampled and controlled trials.

Novavax is always dedicated to developing new products so as to prevent a large number of infectious diseases that could be difficult to treat. The current study would help the company to protect quite a large number of pregnant women and their newborns from contracting RSV disease.